Adicet Bio(ACET) - 2025 Q2 - Quarterly Results

Second Quarter 2025 and Recent Operational Highlights: Autoimmune diseases · First SSc patient dosed in ongoing Phase 1 clinical trial in autoimmune diseases. In July 2025, Adicet announced that the first SSc patient was dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases, in addition to ongoing enrollment in LN and SLE. The Company recently opened enrollment in the Phase 1 trial to include patients with IIM, SPS and AAV. Adicet remains on track to share prelim ...